Author

Stefan Schreiber

IBD management: From the present to the future (Fresenius Kabi)
IBD management: From the present to the future (Fresenius Kabi)

Stefan Schreiber  et al.

EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA
EXPLORATORY ANALYSIS OF FILGOTINIB SAFETY DATA IN A SELECTED POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM FINCH 1–4 AND DARWIN 1–3 STUDIES IN PERSPECTIVE TO INTEGRATED ULCERATIVE COLITIS SAFETY DATA

Stefan Schreiber  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY
SAFETY ANALYSIS OF FILGOTINIB FOR ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY AND PHASE 3 SELECTION LTE LONG-TERM EXTENSION STUDY

Stefan Schreiber  et al.

THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY
THE IMPACT OF BOWEL URGENCY ON THE LIVES OF PATIENTS WITH ULCERATIVE COLITIS IN THE US AND EUROPE: COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Stefan Schreiber  et al.

PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY
PHARMACOKINETICS, EXPOSURE–RESPONSE RELATIONSHIPS, AND IMMUNOGENICITY IN CROHN’S DISEASE PATIENTS WITH USTEKINUMAB SECONDARY LOSS OF RESPONSE FOLLOWING USTEKINUMAB IV RE-INDUCTION: RESULTS FROM THE WEEK 16 ANALYSIS OF THE POWER STUDY

Stefan Schreiber  et al.

NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE
NETWORK META-ANALYSIS TO EVALUATE THE COMPARATIVE EFFICACY OF BIOLOGICS FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH CROHN’S DISEASE

Stefan Schreiber  et al.

Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)
Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)

Stefan Schreiber  et al.

CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL
CLINICAL OUTCOMES AND BIOMARKER NORMALISATION RESPONSE AT WEEK 16 IN PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO PRIOR BIOLOGICS IN THE POWER TRIAL

Stefan Schreiber  et al.

MICROBIOME MODIFICATION AND IMPROVEMENT OF SIGNS AND SYMPTOMS OF COVID-19: ILEOCOLONIC-RELEASE NICOTINAMIDE IN A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL
MICROBIOME MODIFICATION AND IMPROVEMENT OF SIGNS AND SYMPTOMS OF COVID-19: ILEOCOLONIC-RELEASE NICOTINAMIDE IN A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Stefan Schreiber  et al.

GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS
GROUP-BASED TRAJECTORY MODELING TO IDENTIFY RESPONSE PATTERNS TO OZANIMOD TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS

Stefan Schreiber  et al.

EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY
EFFICACY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND PRIOR EXPOSURE TO BIOLOGIC THERAPY: SUBANALYSIS FROM THE PHASE 2 LATTICE-UC STUDY

Stefan Schreiber  et al.

TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY
TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY

Stefan Schreiber  et al.

MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME
MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Stefan Schreiber  et al.

RAPID SYMPTOMATIC RELIEF IS CORRELATED WITH EARLY ENDOSCOPIC RESPONSE TO THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY
RAPID SYMPTOMATIC RELIEF IS CORRELATED WITH EARLY ENDOSCOPIC RESPONSE TO THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY

Stefan Schreiber  et al.

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD STUDY AND LIBERTY-UC STUDY

Stefan Schreiber  et al.

TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY
TRAJECTORY MODELLING TO IDENTIFY DIFFERENT TYPES OF INDIVIDUAL RESPONSE TO THERAPY: A POST HOC ANALYSIS FROM THE SELECTION STUDY

Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)
Precision medicine with precision tools in Crohn’s disease: can we translate science into clinical practice? (Takeda)

Stefan Schreiber  et al.

TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

Item 1 - 20 / 72
1
2 3 4